- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06922175
Reach: RWE: n retrospektiivinen tutkimus, jolla arvioidaan kosbamaattivaikutuksia terveydenhuollon resurssien hyödyntämiseen
Cenobamate'n terveydenhuollon resurssien hyödyntämisen (HCRU) retrospektiivinen arviointi hallitsemattomien fokusoidun kohtausten hallinnassa- Retrospektiivinen, kaaviokatsaustutkimus
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Netherlands
-
Heeze, Netherlands, Alankomaat
- Kempenhaeghe - Academisch Centrum voor Epilepsie
-
-
-
-
Spain
-
Barcelona, Spain, Espanja
- Epilepsy Unit - Neurology Department Valle de Hebron Hospital
-
Madrid, Spain, Espanja
- Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
-
Valencia, Spain, Espanja
- Consorcio Hosp. General Universitario Valencia
-
-
-
-
Germany
-
Freiburg im Breisgau, Germany, Saksa
- Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
-
Hamburg, Germany, Saksa
- Epileptologicum
-
Kork, Germany, Saksa
- Diakonie Kork, Epilepsiezentrum
-
-
-
-
Switzerland
-
Zurich, Switzerland, Sveitsi
- Department of Neurology, University Hospital Zurich
-
-
-
-
UK
-
Glasgow, UK, Yhdistynyt kuningaskunta
- Institute of Neurosciences NHS Greater Glasgow and Clyde
-
Wolverhampton, UK, Yhdistynyt kuningaskunta
- Epilepsies - The Royal Wolverhampton NHS Trust
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.
Kuvaus
Inclusion Criteria:
- Male and female patients of any ethnic origin ≥18 years old at index date;
- Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
- Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
- Patients with at least 6 months of data coverage in the medical records prior to the index date;
- Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
- Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.
Exclusion Criteria:
- Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
- Patients who started cenobamate within an EAP;
- Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
- Patients with specific syndrome (e.g. LGS and Dravet);
- Pregnancy or lactation;
- Patients without self-judgement ability;
- Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
- Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: RETROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Adult patients affected by epilepsy with focal-onset seizures
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits; |
0-12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
Aikaikkuna: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected; |
0-12 months
|
|
Effectiveness of cenobamate used as adjunctive therapy
Aikaikkuna: 0-12 months
|
To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days); |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
Aikaikkuna: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
Aikaikkuna: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
Aikaikkuna: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected. |
0-12 months
|
|
Safety of cenobamate used as adjunctive therapy
Aikaikkuna: 0-12 months
|
To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study. |
0-12 months
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 169(A)AV23432
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .